Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Tg Therapeuticscmn (TGTX)

Tg Therapeuticscmn (TGTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,804,955
  • Shares Outstanding, K 154,543
  • Annual Sales, $ 233,660 K
  • Annual Income, $ 12,670 K
  • 60-Month Beta 2.23
  • Price/Sales 11.77
  • Price/Cash Flow 203.49
  • Price/Book 17.17
Trade TGTX with:

Options Overview Details

View History
  • Implied Volatility 75.18% ( +38.03%)
  • Historical Volatility 46.46%
  • IV Percentile 23%
  • IV Rank 43.39%
  • IV High 160.09% on 08/01/23
  • IV Low 10.10% on 06/10/24
  • Put/Call Vol Ratio 0.20
  • Today's Volume 2,364
  • Volume Avg (30-Day) 3,770
  • Put/Call OI Ratio 0.35
  • Today's Open Interest 102,152
  • Open Int (30-Day) 101,232

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate -0.04
  • Number of Estimates 4
  • High Estimate -0.03
  • Low Estimate -0.06
  • Prior Year -0.34
  • Growth Rate Est. (year over year) +88.24%

Price Performance

See More
Period Period Low Period High Performance
1-Month
15.16 +20.78%
on 06/10/24
19.49 -6.05%
on 06/25/24
+2.01 (+12.33%)
since 05/31/24
3-Month
12.93 +41.61%
on 04/30/24
19.49 -6.05%
on 06/25/24
+3.87 (+26.80%)
since 04/02/24
52-Week
6.46 +183.44%
on 10/16/23
26.95 -32.06%
on 07/10/23
-6.53 (-26.29%)
since 06/30/23

Most Recent Stories

More News
"Rule Breaker Investing" Market Cap Game Show: Bill Mann vs. Bill Barker

Our first-ever twin bill.

AAPL : 220.27 (+1.62%)
QCOM : 200.16 (+0.06%)
AMZN : 200.00 (+1.42%)
MNKD : 5.03 (-1.18%)
SNBR : 9.22 (+2.22%)
MANH : 245.66 (+0.15%)
TGTX : 18.31 (+0.88%)
QRVO : 118.90 (+0.93%)
ZM : 58.34 (-1.47%)
WOOF : 3.11 (-7.86%)
VZ : 41.10 (-1.53%)
MCD : 247.79 (-0.88%)
Global Multiple Sclerosis Drugs Market Size Projected to Reach $38 Billion By 2032 as Demand on R&D for Developing Innovative Drugs Rises

EQNX::TICKER_START (NASDAQ:TLSA),(NYSE:LLY),(OTCQX:RHHBY),(NASDAQ:BIIB),(NASDAQ:TGTX) EQNX::TICKER_END

TLSA : 0.8590 (-3.00%)
LLY : 906.71 (-0.84%)
RHHBY : 34.4300 (-0.61%)
BIIB : 228.82 (-1.27%)
TGTX : 18.31 (+0.88%)
Global Multiple Sclerosis Drugs Market Size Projected to Reach $38 Billion By 2032 as Demand on R&D for Developing Innovative Drugs Rises

TLSA : 0.8590 (-3.00%)
LLY : 906.71 (-0.84%)
RHHBY : 34.4300 (-0.61%)
BIIB : 228.82 (-1.27%)
TGTX : 18.31 (+0.88%)
Why TG Therapeutics Stock Was Rocketing Higher This Week

The company raised guidance for sales of its drug for relapsing multiple sclerosis.

TGTX : 18.31 (+0.88%)
TG Therapeutics: Q1 Earnings Snapshot

TG Therapeutics: Q1 Earnings Snapshot

TGTX : 18.31 (+0.88%)
TG Therapeutics: Q4 Earnings Snapshot

TG Therapeutics: Q4 Earnings Snapshot

TGTX : 18.31 (+0.88%)
Why TG Therapeutics Stock Is Crushing It Today

The biopharmaceutical company's Q3 update was music to investors' ears.

TGTX : 18.31 (+0.88%)
TG Therapeutics: Q3 Earnings Snapshot

TG Therapeutics: Q3 Earnings Snapshot

TGTX : 18.31 (+0.88%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of TG Therapeutics, Inc. - TGTX

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of TG Therapeutics, Inc. ("TG Therapeutics" or the "Company") (NASDAQ: TGTX). Such...

TGTX : 18.31 (+0.88%)
Why TG Therapeutics Stock Is Crashing Today

The drugmaker delivered a couple of surprises in Q2.

TGTX : 18.31 (+0.88%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

TG Therapeutics, Inc. is a biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of cancer and other underserved therapeutic needs. The Company is focused on the development of a monoclonal antibody for the treatment of various...

See More

Key Turning Points

3rd Resistance Point 19.24
2nd Resistance Point 18.84
1st Resistance Point 18.58
Last Price 18.31
1st Support Level 17.92
2nd Support Level 17.52
3rd Support Level 17.26

See More

52-Week High 26.95
Fibonacci 61.8% 19.12
Last Price 18.31
Fibonacci 50% 16.70
Fibonacci 38.2% 14.29
52-Week Low 6.46

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar